Sotera Health (NASDAQ:SHC) Posts Earnings Results

Sotera Health (NASDAQ:SHC) released its quarterly earnings results on Tuesday. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.02, Zacks reports. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. Sotera Health updated its FY 2025 guidance to 0.810-0.860 EPS.

Sotera Health Trading Up 2.0%

SHC opened at $16.94 on Tuesday. The business has a fifty day moving average price of $16.14 and a 200 day moving average price of $13.66. The company has a debt-to-equity ratio of 4.49, a current ratio of 2.47 and a quick ratio of 2.23. Sotera Health has a 12 month low of $9.53 and a 12 month high of $17.68. The stock has a market capitalization of $4.81 billion, a price-to-earnings ratio of 212.44 and a beta of 1.82.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on SHC shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Sotera Health in a research report on Friday. Barclays boosted their price objective on Sotera Health from $17.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Finally, Wall Street Zen upgraded Sotera Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.20.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 8,000,000 shares of Sotera Health stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $15.11, for a total value of $120,880,000.00. Following the completion of the transaction, the director owned 41,215,301 shares in the company, valued at $622,763,198.11. The trade was a 16.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael P. Rutz sold 126,611 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $16.38, for a total transaction of $2,073,888.18. Following the transaction, the insider owned 450,204 shares of the company’s stock, valued at $7,374,341.52. This trade represents a 21.95% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 20,126,611 shares of company stock worth $304,273,888. 47.55% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sotera Health

Several institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its stake in shares of Sotera Health by 831.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock worth $37,000 after purchasing an additional 2,935 shares in the last quarter. Vident Advisory LLC increased its holdings in shares of Sotera Health by 23.9% in the 2nd quarter. Vident Advisory LLC now owns 17,419 shares of the company’s stock valued at $194,000 after acquiring an additional 3,364 shares during the last quarter. Tidal Investments LLC acquired a new stake in shares of Sotera Health during the 2nd quarter worth about $199,000. Boothbay Fund Management LLC purchased a new stake in Sotera Health during the second quarter worth approximately $210,000. Finally, Creative Planning boosted its holdings in Sotera Health by 15.3% in the second quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after purchasing an additional 2,673 shares in the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.